BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 30552025)

  • 1. Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers.
    Pauthner MG; Nkolola JP; Havenar-Daughton C; Murrell B; Reiss SM; Bastidas R; Prévost J; Nedellec R; von Bredow B; Abbink P; Cottrell CA; Kulp DW; Tokatlian T; Nogal B; Bianchi M; Li H; Lee JH; Butera ST; Evans DT; Hangartner L; Finzi A; Wilson IA; Wyatt RT; Irvine DJ; Schief WR; Ward AB; Sanders RW; Crotty S; Shaw GM; Barouch DH; Burton DR
    Immunity; 2019 Jan; 50(1):241-252.e6. PubMed ID: 30552025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody responses induced by SHIV infection are more focused than those induced by soluble native HIV-1 envelope trimers in non-human primates.
    van Schooten J; van Haaren MM; Li H; McCoy LE; Havenar-Daughton C; Cottrell CA; Burger JA; van der Woude P; Helgers LC; Tomris I; Labranche CC; Montefiori DC; Ward AB; Burton DR; Moore JP; Sanders RW; Crotty S; Shaw GM; van Gils MJ
    PLoS Pathog; 2021 Aug; 17(8):e1009736. PubMed ID: 34432859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The C3/465 glycan hole cluster in BG505 HIV-1 envelope is the major neutralizing target involved in preventing mucosal SHIV infection.
    Charles TP; Burton SL; Arunachalam PS; Cottrell CA; Sewall LM; Bollimpelli VS; Gangadhara S; Dey AK; Ward AB; Shaw GM; Hunter E; Amara RR; Pulendran B; van Gils MJ; Derdeyn CA
    PLoS Pathog; 2021 Feb; 17(2):e1009257. PubMed ID: 33556148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.
    Someya K; Cecilia D; Ami Y; Nakasone T; Matsuo K; Burda S; Yamamoto H; Yoshino N; Kaizu M; Ando S; Okuda K; Zolla-Pazner S; Yamazaki S; Yamamoto N; Honda M
    J Virol; 2005 Feb; 79(3):1452-62. PubMed ID: 15650171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates.
    Wang Y; O'Dell S; Turner HL; Chiang CI; Lei L; Guenaga J; Wilson R; Martinez-Murillo P; Doria-Rose N; Ward AB; Mascola JR; Wyatt RT; Karlsson Hedestam GB; Li Y
    J Virol; 2017 Nov; 91(21):. PubMed ID: 28835491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines.
    Excler JL; Ake J; Robb ML; Kim JH; Plotkin SA
    Clin Vaccine Immunol; 2014 Aug; 21(8):1023-36. PubMed ID: 24920599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates.
    Saunders KO; Santra S; Parks R; Yates NL; Sutherland LL; Scearce RM; Balachandran H; Bradley T; Goodman D; Eaton A; Stanfield-Oakley SA; Tartaglia J; Phogat S; Pantaleo G; Esteban M; Gomez CE; Perdiguero B; Jacobs B; Kibler K; Korber B; Montefiori DC; Ferrari G; Vandergrift N; Liao HX; Tomaras GD; Haynes BF
    J Virol; 2018 Apr; 92(8):. PubMed ID: 29437967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study.
    Ferrantelli F; Maggiorella MT; Schiavoni I; Sernicola L; Olivieri E; Farcomeni S; Pavone-Cossut MR; Moretti S; Belli R; Collacchi B; Srivastava IK; Titti F; Cafaro A; Barnett SW; Ensoli B
    Vaccine; 2011 Apr; 29(16):2918-32. PubMed ID: 21338681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breakthrough of SIV strain smE660 challenge in SIV strain mac239-vaccinated rhesus macaques despite potent autologous neutralizing antibody responses.
    Burton SL; Kilgore KM; Smith SA; Reddy S; Hunter E; Robinson HL; Silvestri G; Amara RR; Derdeyn CA
    Proc Natl Acad Sci U S A; 2015 Aug; 112(34):10780-5. PubMed ID: 26261312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccine induction of antibodies and tissue-resident CD8+ T cells enhances protection against mucosal SHIV-infection in young macaques.
    Petitdemange C; Kasturi SP; Kozlowski PA; Nabi R; Quarnstrom CF; Reddy PBJ; Derdeyn CA; Spicer LM; Patel P; Legere T; Kovalenkov YO; Labranche CC; Villinger F; Tomai M; Vasilakos J; Haynes B; Kang CY; Gibbs JS; Yewdell JW; Barouch D; Wrammert J; Montefiori D; Hunter E; Amara RR; Masopust D; Pulendran B
    JCI Insight; 2019 Feb; 4(4):. PubMed ID: 30830870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a tier 1 R5 clade C simian-human immunodeficiency virus as a tool to test neutralizing antibody-based immunoprophylaxis.
    Siddappa NB; Hemashettar G; Wong YL; Lakhashe S; Rasmussen RA; Watkins JD; Novembre FJ; Villinger F; Else JG; Montefiori DC; Ruprecht RM
    J Med Primatol; 2011 Apr; 40(2):120-8. PubMed ID: 21044092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human Immunodeficiency Virus C.1086 Envelope gp140 Protein Boosts following DNA/Modified Vaccinia Virus Ankara Vaccination Fail To Enhance Heterologous Anti-V1V2 Antibody Response and Protection against Clade C Simian-Human Immunodeficiency Virus Challenge.
    Styles TM; Gangadhara S; Reddy PBJ; Hicks S; LaBranche CC; Montefiori DC; Derdeyn CA; Kozlowski PA; Velu V; Amara RR
    J Virol; 2019 Oct; 93(20):. PubMed ID: 31341049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers.
    Hessell AJ; Rakasz EG; Poignard P; Hangartner L; Landucci G; Forthal DN; Koff WC; Watkins DI; Burton DR
    PLoS Pathog; 2009 May; 5(5):e1000433. PubMed ID: 19436712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques.
    Klasse PJ; Ketas TJ; Cottrell CA; Ozorowski G; Debnath G; Camara D; Francomano E; Pugach P; Ringe RP; LaBranche CC; van Gils MJ; Bricault CA; Barouch DH; Crotty S; Silvestri G; Kasturi S; Pulendran B; Wilson IA; Montefiori DC; Sanders RW; Ward AB; Moore JP
    PLoS Pathog; 2018 Feb; 14(2):e1006913. PubMed ID: 29474444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Closing and Opening Holes in the Glycan Shield of HIV-1 Envelope Glycoprotein SOSIP Trimers Can Redirect the Neutralizing Antibody Response to the Newly Unmasked Epitopes.
    Ringe RP; Pugach P; Cottrell CA; LaBranche CC; Seabright GE; Ketas TJ; Ozorowski G; Kumar S; Schorcht A; van Gils MJ; Crispin M; Montefiori DC; Wilson IA; Ward AB; Sanders RW; Klasse PJ; Moore JP
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30487280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant.
    Barnett SW; Burke B; Sun Y; Kan E; Legg H; Lian Y; Bost K; Zhou F; Goodsell A; Zur Megede J; Polo J; Donnelly J; Ulmer J; Otten GR; Miller CJ; Vajdy M; Srivastava IK
    J Virol; 2010 Jun; 84(12):5975-85. PubMed ID: 20392857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multimodality vaccination against clade C SHIV: partial protection against mucosal challenges with a heterologous tier 2 virus.
    Lakhashe SK; Byrareddy SN; Zhou M; Bachler BC; Hemashettar G; Hu SL; Villinger F; Else JG; Stock S; Lee SJ; Vargas-Inchaustegui DA; Cofano EB; Robert-Guroff M; Johnson WE; Polonis VR; Forthal DN; Loret EP; Rasmussen RA; Ruprecht RM
    Vaccine; 2014 Nov; 32(48):6527-36. PubMed ID: 25245933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers.
    Capucci S; Wee EG; Schiffner T; LaBranche CC; Borthwick N; Cupo A; Dodd J; Dean H; Sattentau Q; Montefiori D; Klasse PJ; Sanders RW; Moore JP; Hanke T
    PLoS One; 2017; 12(8):e0181886. PubMed ID: 28792942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunization with wild-type or CD4-binding-defective HIV-1 Env trimers reduces viremia equivalently following heterologous challenge with simian-human immunodeficiency virus.
    Sundling C; O'Dell S; Douagi I; Forsell MN; Mörner A; Loré K; Mascola JR; Wyatt RT; Karlsson Hedestam GB
    J Virol; 2010 Sep; 84(18):9086-95. PubMed ID: 20610729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of HIV-specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV-capturing nanospheres in macaques.
    Miyake A; Akagi T; Enose Y; Ueno M; Kawamura M; Horiuchi R; Hiraishi K; Adachi M; Serizawa T; Narayan O; Akashi M; Baba M; Hayami M
    J Med Virol; 2004 Jul; 73(3):368-77. PubMed ID: 15170630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.